ClinicalTrials.gg
CompletedNCT05667779Updated Apr 15, 2024

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

A Phase 1 interventional study of QRL-101 and Placebo in Healthy Volunteers, sponsored by QurAlis Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by QurAlis Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending single doses of QRL-101 in male and female healthy participants. The findings from this study will be used to inform the development of QRL-101 for people living with ALS.

Read the detailed description

Phase 1, single-site study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending single doses of QRL-101 administered orally in healthy male and female participants. Up to 16 cohorts of 8 participants each, randomized 6:2 (QRL-101: placebo) will be tested. The approximate total duration of study participation for each participant may be up to 40 days.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

QurAlis Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 70 years of age inclusive at the time of signing the .
  2. Clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment.
  3. of 18 to 32 kg/m2 (inclusive).
  4. Willing and able to practice effective .

Exclusion criteria

EXCLUSION CRITERIA

  1. Currently enrolled in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study.
  2. Any participant in >4 studies a year and/or has participated in a clinical trial within 1 month of expected dosing date.
  3. History or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation.

*Other inclusion and exclusion criteria may apply*

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    QRL-101

    Single-ascending doses of QRL-101 will be administered orally to healthy participants

    Drug: QRL-101

  • Placebo comparator
    Placebo

    Single-ascending doses of comparator placebo will be administered orally to healthy participants

    Other: Placebo

Interventions

  • Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

  • OtherPlacebo

    A placebo comparator will be administered at all dose levels.

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more treatment emergent adverse events and serious adverse events.

    Endpoints: A summary of treatment emergent adverse events (AEs), serious adverse events (SAEs), and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline through Follow up (Day 10)

Secondary outcomes

  1. Pharmacokinetics (plasma): Maximum observed concentration of QRL-101

    Endpoint: Maximum observed concentration (Cmax) of QRL-101

    Time frame: Baseline through Follow up (Day 10)

  2. Pharmacokinetics (plasma): Area under the concentration time curve from 0 to 24 h (AUC 0-24h) of QRL-101

    Endpoint: Area under the concentration time curve from zero to infinity (AUC 0-24h) of QRL-101

    Time frame: Baseline through Follow up (Day 10)

  3. Pharmacokinetics (plasma): Time of maximum concentration of QRL-101

    Endpoint: Time of maximum concentration (Tmax) of QRL-101

    Time frame: Baseline through Follow up (Day 10)

07

Study locations

1 site
  • ICON plc. Van Swietenlaan 6
    Groningen, 9728 NZ, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Dec 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2022
First posted
Dec 29, 2022
StartActual
Dec 22, 2022
Primary completionActual
Dec 27, 2023
CompletionActual
Dec 27, 2023
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05667779
Lead sponsor
QurAlis Corporation
Responsible party
Sponsor
First posted
Dec 29, 2022
Start date
Dec 22, 2022
Primary completion
Dec 27, 2023
Completion
Dec 27, 2023
Last update
Apr 15, 2024

Study contacts

Salah Hadi, MD
principal investigator · ICON plc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRL-101

Start the discussion